NCT04123418View on ClinicalTrials.gov

A Study of WVT078 in Patients With Multiple Myeloma (MM)

PHASE1TerminatedINTERVENTIONAL
Enrollment

56

Participants

Timeline

Start Date

December 5, 2019

Primary Completion Date

December 2, 2024

Study Completion Date

December 2, 2024

Conditions
Multiple Myeloma (MM)
Interventions
BIOLOGICAL

WVT078

WVT078 will be administered IV (intravenously) in a dose escalation schedule

DRUG

WHG626

WHG626 will be administered orally in a dose escalation schedule

Trial Locations (12)

3004

Novartis Investigative Site, Melbourne

20162

Novartis Investigative Site, Milan

30322

Emory University School of Medicine-Winship Cancer Institute, Atlanta

39008

Novartis Investigative Site, Santander

53226

Medical College of Wisconsin, Milwaukee

53792

University Of Wisconsin, Madison

69120

Novartis Investigative Site, Heidelberg

6423906

Novartis Investigative Site, Tel Aviv

01307

Novartis Investigative Site, Dresden

113-8677

Novartis Investigative Site, Bunkyo Ku

NO-0407

Novartis Investigative Site, Oslo

08041

Novartis Investigative Site, Barcelona

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY